PharmaDepth

Company profile

BEONE MEDICINES LTD.

NASDAQ:ONCBiotechnology: Pharmaceutical Preparations

Drug pipeline (7)

AssetStageRevenueTrialsStatus
BRUKINSAapproved$1.2BQ2 202644approved
TEVIMBRAapproved$228.5MQ2 20260—
BEQALZIapproved—19approved
TEVIMBRAapproved—0—
PAMIPARIBphase3—11active

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (185)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05006716phase1_2recruiting2021-09-132027-03-01BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT06625593phase1recruiting2024-12-092026-12-31BeOne MedicinesA First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT07746141phase1recruiting2026-09-022028-09-30BeOne MedicinesA First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
NCT07181681phase1recruiting2025-11-102027-11-01BeOne MedicinesA First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07414836phase1recruiting2026-04-132029-04-30BeOne MedicinesA First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

FDA applications (6)

ApplicationApprovedTypeApplicantProducts
NDA 2207112026-05-13NDABEONE MEDICINES USA INC
NDA 2187852025-06-10NDABEONE MEDICINES USA INC
BLA 7612322024-03-13BLABEONE MEDICINES USA, INC.
NDA 2132172019-11-14NDABEONE MEDICINES USA INC
BLA 761380—BLABEIGENE